

1 **Serum antibodies to surface proteins of *Chlamydia trachomatis* as candidate**  
2 **biomarkers of disease: Results from the Baltimore Chlamydia Adolescent/Young**  
3 **Adult Reproductive Management (CHARM) cohort.**

4 Patricia X. Marques PhD<sup>a</sup>, Handan Wand PhD<sup>b</sup>, Melissa Nandy MSc<sup>c</sup>, Chun Tan PhD<sup>a</sup>,  
5 Huizhong Shou BS<sup>a</sup>, Mishka Terplan PhD<sup>d</sup>, Katrina Mark MD<sup>e</sup>, Rebecca M. Brotman  
6 PhD<sup>c</sup>, David P. Wilson PhD<sup>f</sup>, Jacques Ravel PhD<sup>g,c</sup>, Ru-ching Hsia PhD<sup>h</sup> and Patrik M.  
7 Bavoil PhD<sup>a</sup>

8 Depts of <sup>a</sup>Microbial Pathogenesis, <sup>d</sup>Obstetrics & Gynecology, <sup>e</sup>Pediatrics and  
9 <sup>g</sup>Microbiology and Immunology, <sup>c</sup>Institute for Genome Science, and <sup>h</sup>Electron  
10 Microscopy Core Imaging Facility, University of Maryland, Baltimore, Maryland, USA;  
11 <sup>b</sup>The Kirby Institute, University of New South Wales, Sydney, Australia; <sup>f</sup>The Burnet  
12 Institute, Melbourne, Australia

13 **Corresponding author:** Patrik M Bavoil, Dept of Microbial Pathogenesis, University of  
14 Maryland School of Dentistry, 650 W. Baltimore St., Baltimore, MD 21201. Tel: 410 706  
15 6789; Fax: 410 706 0865; e-mail: [pbavoil@umaryland.edu](mailto:pbavoil@umaryland.edu).

16  
17 **Word counts:** Summary: 20; Abstract: 240; Text: 2,719

18 Number of references: 33; Number of figures: 2; Number of tables: 4

19 **Conflicts of Interest and Source of Funding**

20 The authors do not have a commercial or other association that might pose a conflict of  
21 interest (e.g., pharmaceutical stock ownership, consultancy, advisory board  
22 membership, relevant patents, or research funding).

23 Research reported in this publication was supported by the National Institute of Allergy  
24 and Infectious Diseases of the National Institutes of Health under award number  
25 U19AI084044. The content is solely the responsibility of the authors and does not  
26 necessarily represent the official views of the National Institutes of Health  
27

28 **Acknowledgements**

29 The contributions of Esther Colinetti, Nyaradzo Longinaker, Anup Mahurkar and Dr. Ligia  
30 Peralta to the development of the CHARM cohort are gratefully acknowledged.  
31

32 **Short Summary**

33 Serological analysis of the CHARM cohort shows an association of the serum antibody  
34 response against OmcB and pelvic inflammatory disease.

35

36 **Abstract**

37 **Background:** We previously observed that the nine-member family of autotransported  
38 polymorphic membrane proteins (Pmps) of *Chlamydia trachomatis* is variably expressed  
39 in cell culture. Additionally, *C. trachomatis*-infected patients display variable Pmp-specific  
40 serum antibody profiles indirectly suggesting expression of unique Pmp profiles is an  
41 adaptive response to host-specific stimuli during infection. Here, we propose that the host  
42 response to Pmps and other outer surface proteins may correlate with disease severity.

43 **Methods:** This study tests this hypothesis using an ELISA that measures serum IgG  
44 antibodies specific for the nine *C. trachomatis* Pmp subtypes and four immunodominant  
45 antigens (MOMP, OmcB, GroEL, ClpP) in 265 participants of the *Chlamydia*  
46 Adolescent/Young Adult Reproductive Management (CHARM) cohort.

47 **Results:** More *C. trachomatis*-infected females displayed high Pmp-specific antibody  
48 levels (cut-off Indexes) than males (35.9-40.7% of females vs. 24.2-30.0% of males), with  
49 statistical significance for PmpC, F and H ( $P < 0.05$ ). Differences in Pmp-specific antibody  
50 profiles were not observed between *C. trachomatis*-infected females with a clinical  
51 diagnosis of pelvic inflammatory disease (PID) and those without. However, a statistically  
52 significant association between high levels of OmcB-specific antibody and a PID  
53 diagnosis ( $P < 0.05$ ) was observed.

54 **Conclusions:** Using antibody levels as an indirect measure of antigen expression, our  
55 results suggest that gender- and/or site-specific (cervix in females vs. urethra in males)  
56 stimuli control *pmp* expression in infected patients. They also support the possible  
57 existence of immune biomarkers of chlamydial infection associated with disease and  
58 underline the need for high resolution screening in human serum.

59

60 **Keywords:** *Chlamydia trachomatis*, polymorphic membrane proteins, surface proteins,  
61 serology, ELISA, antibodies, pelvic inflammatory disease

62

## 63 INTRODUCTION

64 In 2018, more than 1.8 million cases of sexually transmitted *Chlamydia trachomatis*  
65 infection in the United States were reported to the Centers for Disease Control and  
66 Prevention (1). Chlamydial infections, which are often asymptomatic, can lead to pelvic  
67 inflammatory disease (PID), a precursor of female infertility, ectopic pregnancy, and  
68 chronic pelvic pain in 10-20% of infected women. Screening for *C. trachomatis* using  
69 nucleic acid amplification tests followed by treatment, can reduce the incidence of PID by  
70 as much as 60% (2), suggesting that detection of an active chlamydial infection is an  
71 effective means of reducing future sequelae. To fully control chlamydial disease however,  
72 host or chlamydial biomarkers that can discriminate between different clinical outcomes  
73 early in, or during, infection remain highly desirable.

74 A panoply of secreted and/or surface proteins of *C. trachomatis* are thought to act  
75 early in infection (3-6) as adhesins and/or invasins. These include the elementary body  
76 (EB)-specific cysteine-rich outer membrane complex protein OmcB (5), the major outer  
77 membrane protein MOMP (OmpA) (7), and members of the polymorphic membrane  
78 protein family (Pmps) (8). The late-expressed cysteine-rich protein OmcB was previously  
79 suggested as a candidate adhesin for *C. trachomatis* (9), *Chlamydia caviae* (3), and more  
80 recently for *Chlamydia pneumoniae* (5). MOMP displays sequence-variable domains  
81 defining 17 serovars categorized according to tissue tropism (A-C, ocular; D-K, urogenital;  
82 L1-L3, inguinal lymph nodes), and was also proposed to function as an adhesin for *C.*  
83 *trachomatis* (10). The 9-member *pmp* gene family of *C. trachomatis* (Pmp subtypes A-I;  
84 (11)) is predicted to be associated with tissue tropism (12). *C. trachomatis* PmpD-specific  
85 antibody has been shown to dramatically reduce infection *in vitro* (6, 13). These properties

86 and the observed on/off switching of expression of the Pmps in cell culture (8, 14) suggest  
87 that production of a specific Pmp subtype(s) may be required and/or selected for at  
88 different sites or stages of infection. Consistent with variable expression in cell culture,  
89 we have previously shown that all *C. trachomatis*-infected patients mount a strong  
90 serologic response against different subsets of Pmps (15) with a suggested correlation  
91 between disease (PID) and Pmpl antibody titer (15, 16).

92 The presence at the chlamydial surface of specific OmcB and MOMP types  
93 combined with the expression of diverse PmpA-I profiles may provide the outer coat  
94 diversity that is necessary for adherence to, internalization by and colonization of diverse  
95 mucosal sites. Since sites of infection may be associated with a spectrum of pathologies  
96 ranging from none to severe, we further propose that distinct outer surface protein profiles  
97 may also correlate with disease severity. Here we indirectly test these two linked  
98 hypotheses using an antibody capture ELISA to evaluate the host response to OmcB and  
99 MOMP, and as a surrogate for the expression of specific Pmp subtypes. We use serum  
100 samples from participants in the *Chlamydia* Adolescent/Young Adult Reproductive  
101 Management (CHARM) cohort enrolled in the Baltimore, Maryland area. To address  
102 site/gender specific expression, sera from *C. trachomatis*-infected men and women are  
103 compared. To address the possible link with disease severity, sera from women with a  
104 lower genital tract *C. trachomatis* infection and a reported PID diagnosis are compared  
105 with those without a PID diagnosis. Because of their previously reported association with  
106 disease in other studies, the *C. trachomatis* Heat Shock Protein GroEL (Hsp60) (17-19)  
107 and the Caseinolytic protease P (ClpP) (19) are also included.

108

## 109 **METHODS**

### 110 **CHARM cohort**

111 The Chlamydia Adolescent & Young Adult Reproductive Management (CHARM)  
112 cohort consists of 276 *Chlamydia trachomatis*-infected men and women recruited  
113 between September 2010 and December 2013 in the Baltimore area (Table 1). CHARM  
114 inclusion and exclusion criteria, informed consent, treatment, data and specimens  
115 collected at entry and at intervals, follow-up activities, and statistical analyses were  
116 published independently (20). CHARM (HP-00042320) was reviewed and approved by  
117 the Institutional Review Board of the University of Maryland Baltimore. For the purpose  
118 of this study, blood was collected without additives at enrollment and prior to antibiotic  
119 treatment. After centrifugation, serum samples were stored at -20°C until analyzed. PID  
120 diagnosis was based on the minimum clinical criteria (cervical motion tenderness, uterine  
121 tenderness or adnexal tenderness) as set by the Centers for Disease Control and  
122 Prevention (21).

123

### 124 **Recombinant polypeptides**

125 The predicted passenger domains of PmpC, D, E, F, H and I, smaller fragments of  
126 PmpA (*pmpA-F2*), PmpB (*pmpB-F1* and *pmpB-F2*) and PmpG (Figure 1) (15), rMOMP  
127 rGroEL, rOmcB and rClpP (from *C. trachomatis* serovar D; kindly provided by Dr.  
128 Guangming Zhong) were expressed in *E. coli* BL21(DE3) and purified as indicated in  
129 Table S1 (*Supplemental Digital Content 1 listing characteristics and purification*  
130 *conditions of the recombinant polypeptides*).

131 Insoluble polypeptides (all except rGroEL) were solubilized overnight at 42°C in 8 M  
132 urea/10 mg/ml Octyl beta-D-glucopyranoside (OGP) in buffer (50 mM Tris-HCl, pH 8/1  
133 mM EDTA/1 mM DTT), dialyzed against 0.01% OGP and affinity purified (*Table S1, in*  
134 *Supplemental Digital Content 1*).

135 Purification was monitored by SDS-PAGE and immunoblot (*see Figure S1, in*  
136 *Supplemental Digital Content 1, which shows Expression and purification of all the*  
137 *recombinant proteins and peptides used in this study*).

138

### 139 **ELISA**

140 Microplates PS (F-form; Greiner Bio-One North America, Inc.) coated with EBs  
141 purified from 48h *C. trachomatis* serovar E cultures and *C. pneumoniae* AR39 (22) (*see*  
142 *Table S2 in Supplemental Digital Content 1, that lists the ELISA optimized conditions*) or  
143 purified recombinant polypeptides (*see Table S2, in Supplemental Digital Content 1*) were  
144 incubated overnight at 4°C, washed with PBS-T and blocked with 2.5% milk. ELISA was  
145 performed as described (23) using diluted CHARM sera (*Table S2, Supplemental Digital*  
146 *Content 1*) and goat anti-human IgG peroxidase labeled antibody (1:2000 dilution; 100  
147 µl/well; KPL, Inc.). Results were read in a Beckman DTX 880 plate reader (Beckman  
148 Coulter, Inc.) at 450 and 620 nm (background).

149 Results obtained by ELISA were comparable to those previously obtained by  
150 immunoblot analysis and densitometry (15) (not shown), thus supporting the validity of  
151 results obtained by either method. ELISA results generated with GST•tagged and  
152 His•tagged OmcB were positively correlated ( $p < 0.001$ ; *see Figure S2, in Supplemental*

153 *Digital Content 1, a graphic of the correlation between G-OmcB and H-OmcB*), further  
154 validating the ELISA.

155

## 156 **Statistical analysis**

157 Chi-squared test was used to compare the demographic, sexual behavior and  
158 biological factors of the study groups. Median and inter-quartile ranges were used to  
159 describe continuous variables. A non-parametric test was used to compare the median  
160 by gender.

161 Antibody levels defined as the cut-off Indexes for rPmpA to I, rClpP, rHsp60,  
162 rMOMP, rOmcB and *C. trachomatis* purified EBs were used as categorical variables and  
163 split into tertiles. The first tertile cut-point represented the lower, while the third tertile  
164 represented the higher cut-off indexes. Logistic regression models were then used to  
165 determine the association between cut-off indexes in the first and third tertiles  
166 (highest/lowest) and PID diagnosis (outcome). Unadjusted and adjusted Odds Ratios  
167 (ORs) and their 95% confidence intervals (CIs) were calculated. In adjusted analysis,  
168 results were presented after accounting for potential confounding effects of age,  
169 *Trichomonas vaginalis* infection and a diagnosis of bacterial vaginosis (BV) based on  
170 Amsel's criteria (24).

171 All analyses were performed using Stata 12.0 (College Station).

172



173 **RESULTS**

174 **Demographics and sexual behavior in the CHARM cohort**

175 A total of 265 participants (120 males, 45.3% and 145 females, 54.7%) of the  
176 CHARM cohort were included in the study. The overall median age of the study population  
177 was 19.5 years old (IQR: 17-21). Males were more likely to be older (median: 20.2 years,  
178 IQR: 18-22) compared to women (18.9 years, IQR: 17-21 respectively) ( $p=0.0047$ ). Table  
179 1 compares demographic data, sexual behavior, sexual history and past and current  
180 diagnosis of sexually transmitted infections (STIs) in men and women of the CHARM  
181 cohort (20). Most of the study population reported having first vaginal intercourse before  
182 age 13 years (84.2%). Females were more likely to report a sexual debut before age 13  
183 years (86.7 females vs. 77.5%, males,  $p=0.007$ ). The majority of the participants (64.5%)  
184 reported having 6 or more lifetime sexual partners. Male participants were more likely  
185 than females to report 6+ sexual partners (53.1% females vs. 78.3% males,  $p<0.001$ ).  
186 There were no significant differences reported for receptive oral or anal sex based on  
187 gender. Of the 145 CHARM female participants whose samples were analyzed by ELISA,  
188 126 (86.9%) were heterosexual, one (0.7%) was homosexual and 18 (12.4%) were  
189 bisexual. Thirty seven (25.5%) reported receptive anal sex. Of the CHARM 120 male  
190 participants, 105 (87.5%) were heterosexual, 9 (7.5%) were homosexual and 6 (5%)  
191 bisexual. Thirteen (10.8%) reported receptive anal sex. Overall, 12.0% of the participants  
192 reported condom use in the last 3 months and females were significantly less likely to  
193 report having sex with partners who used condoms compared to males (7.6% females  
194 vs. 17.5% males,  $p=0.014$ ). Most of the CHARM participants were African Americans or  
195 of Hispanic/Latino ethnicity.

196

197 **Factors associated with pelvic inflammatory disease (PID) in the females of the**  
198 **CHARM cohort**

199 Of the 145 CT+ female participants from the CHARM cohort, 33 (22.8%) were  
200 clinically diagnosed as having PID at the study visit (Table 2). We assessed associations  
201 between a PID diagnosis with various demographic and sexual risk factors. Participants  
202 self-reporting previous *T. vaginalis* infection (OR: 2.79, 95% CI: 1.15 – 6.80, p-  
203 value=0.0230.025), and previous PID (OR: 19.82, 95% CI: 2.23 – 176.52, p-value=0.007)  
204 were more likely to be diagnosed with PID at study entry.

205

206 **The serum Pmp-specific antibody profile of *C. trachomatis*-infected CHARM**  
207 **participants is associated with gender**

208 *C. trachomatis* and *C. pneumoniae* purified EBs and recombinant antigen ELISA  
209 were used to analyze serum antibodies (IgG) of 265 patients (145153 females and 120  
210 males) from the CHARM cohort. Most participants had an antibody response against H-  
211 rOmcB, H-rPmpC, G-rHsp60, and H-rPmpI with sensitivity above 85% (Table S3,  
212 *Supplemental Digital Content 1*). The antibody response against *C. pneumoniae* purified  
213 EBs was very low with only 3 samples (1.1%) with slightly elevated antibody levels.

214 Potential association between serum antibody levels (grouped in tertiles) and  
215 gender was investigated. Overall, when compared to males, a higher proportion of  
216 females were in the top tertile across all Pmps (35.9-40.7% for females vs. 24.2-30.0%  
217 for males; Table 3). Significant gender differences were observed for rPmps subtypes H-  
218 rPmpC-N (39.3% vs. 25.8%, p=0.001 for females and males respectively), H-rPmpF-N

219 (36.6% vs 29.2%,  $p=0.020$ ) and rPmpH-N (40.7% vs 24.2%,  $p=0.018$ ). Trending statistical  
220 significance was observed for G-rPmpA-F2 (39.3% vs. 25.8%,  $p=0.068$ ), and H-rPmpE-  
221 N (39.3% vs. 25.8%,  $p=0.063$ ). For G-MOMP, a significant proportion of males were in  
222 the lower tertile when compared to females (26.2% vs. 42.5%,  $p=0.011$ ). Gender-based  
223 differences were not detected for other recombinant peptides.

224

225 **The serum OmcB-specific antibody response is associated with a clinical**  
226 **diagnosis of pelvic inflammatory disease (PID) in *C. trachomatis*-infected female**  
227 **CHARM participants**

228 High antibody levels against H-rOmcB (Figure 2; Table 4 and see S4, in  
229 *Supplemental Digital Content 1, showing associations between factors (in tertiles)*  
230 *associated with PID diagnosis with tertiles calculated only for females*; OR: 2.31, 95% CI:  
231 0.72-7.46,  $p=0.160$  and OR: 4.22, 95% CI: 1.37-13.01,  $p=0.012$ , respectively) were  
232 significantly associated with a clinical diagnosis of PID. Similar results were obtained for  
233 G-rOmcB (Figure 2; Tables 4 and S4) *associated with PID diagnosis with tertiles*  
234 *calculated only for females*; OR: 2.58, 95% CI: 0.87-7.63,  $p=0.087$ /second vs. first tertile,  
235 OR: 2.56, 95% CI: 0.86-7.65,  $p=0.091$ /third vs. first tertile).

236 In contrast, antibodies to the other tested antigens were not individually associated  
237 with PID with any statistical significance. Antibody levels for the second and third tertiles  
238 were almost identical for Hsp60 and MOMP (Figure 2.). Similarly, antibody levels against  
239 each of the Pmp subtypes were not significantly associated with PID, although the  
240 response to H-rPmpI was borderline significant (Figure 2; OR: 2.52, 95% CI: 0.89-7.11,  
241  $p=0.075$ /first vs. second tertile). Interestingly, however, antibody levels against 8 of the 9

242 rPmp subtypes (all but H-rPmpF) were slightly higher in women without a clinical  
243 diagnosis of PID, although none reached statistical significance individually. This  
244 suggests a global negative association of antibodies against the Pmp family and upper  
245 genital tract disease.

## 246 **DISCUSSION AND CONCLUSIONS**

247 An ELISA was developed to measure antibody levels against recombinant  
248 polypeptides derived from the 9 *C. trachomatis* Pmps, the EB-specific OmcB, MOMP,  
249 ClpP, and the stress response protein GroEL, in 265 chlamydia-positive male and female  
250 participants of the CHARM cohort from the Baltimore area. All participants exhibited an  
251 antibody response to *C. trachomatis* purified EBs and at least one of the Pmps. While  
252 female CHARM participants had proportionally higher antibody levels to all Pmps  
253 compared to males, statistically significant gender differences were observed for 3 Pmps  
254 (rPmpC, F and H). The higher antibody levels in females are consistent with previous  
255 reports of sex differences in antibody responses (reviewed in (25)). However, since *C.*  
256 *trachomatis* infection in men and women is diagnosed at different sites (the cervix in  
257 women and urethra in men), these findings are also consistent with the hypothesis that  
258 different Pmps may be expressed differentially in different anatomical sites and/or  
259 physiological environments.

260 Statistically significant differences in anti-Pmp antibody levels were not detected  
261 when comparing female CHARM participants with or without a positive clinical diagnosis  
262 for PID, indicating that the Pmp-specific antibody response is not significantly altered  
263 when the infection ascends to the upper genital tract compared to when it is limited to the  
264 lower genital tract. In turn, this suggests that the expressed Pmp profile of *C. trachomatis*-  
265 infected women is independent of the site of infection along the reproductive tract.  
266 Although Pmp-based differences were not observed, CHARM participants with a clinical  
267 PID diagnosis were more likely to have high antibody levels against OmcB than those  
268 without. This is consistent with previous reports of OmcB being associated with CD8+ T

269 cell-mediated upper genital tract immunopathology (26). In contrast, antibody levels were  
270 almost identical for GroEL and MOMP, suggesting that these antigens are not associated  
271 with upper genital tract infection and PID, consistent with previous findings for GroEL (27)  
272 and MOMP (28). Our study failed to confirm the reported association of ClpP-specific  
273 antibodies with upper genital tract disease (19). However, this earlier study involved a  
274 different end point (tubal factor infertility) and a smaller cohort.

275 Overall, the observation of different antibody responses to specific Pmp subtypes  
276 in *C. trachomatis*-infected patients relative to gender and/or site of infection, while  
277 compatible with the hypothesized site-specific expression of Pmps in the context of  
278 infection, falls short of providing indisputable evidence for it, and does not lend confidence  
279 that these antigens are exploitable for sero-diagnosis. Multiple behavioral, immunological  
280 and structural factors have historically confounded or limited serologic analyses of  
281 chlamydial antigens for diagnostic purposes. For instance, potential cross-reactivity with  
282 orthologous antigens owing to *Chlamydia pneumoniae* (29) or *Chlamydia psittaci* (30)  
283 previous or concurrent infections, gender-associated differential immune responses (25),  
284 co-infection with other STIs, repeat infection with *C. trachomatis* or concurrent infection  
285 at multiple sites, as well as non-native structural features of recombinant antigens, are  
286 potential limitations of any approach toward reliable sero-diagnosis. Conversely, any  
287 statistically significant serologic difference that is detectable above the background ‘noise’  
288 generated by these confounding factors and limitations should be exploitable as a  
289 diagnostic or prognostic tool. In this context, our findings that OmcB-specific serum  
290 antibody levels were elevated in women with a PID diagnosis suggests that this antigen  
291 is worthy of further study as a biomarker of upper genital tract disease. For instance, the

292 possibility of determining whether an asymptomatic *C. trachomatis*-infected woman is  
293 likely to develop or already has subclinical upper genital tract pathology (silent PID; (31))  
294 via a simple measurement of OmcB-specific antibody would be of great benefit to the  
295 physician and ultimately to his/her patient. Although cross-reactive antibody responses  
296 against *C. pneumoniae* OmcB have been reported (32), Gijzen et al. (33) also showed  
297 that tubal pathology was more common in patients with both *C. pneumoniae* and *C.*  
298 *trachomatis* antibodies compared to patients with antibodies against OmcB from only one  
299 *Chlamydia* species, further strengthening a role for this well-conserved chlamydial protein  
300 in eliciting pathology.

301

302 In conclusion, our expanded analysis of the observed Pmp-specific antibody profile  
303 variation in *C. trachomatis*-infected men and women of the CHARM cohort may reflect  
304 the hypothesized differential expression of different Pmp profiles as a prerequisite or in  
305 response to infection of distinct urogenital sites. However other possibilities exist that  
306 suggest that these antigens may be impractical to use as serologic biomarkers. Our study  
307 also revealed an association between a high OmcB-specific serum antibody level and a  
308 PID diagnosis. This finding corroborates previous studies (18) and indicates that this  
309 protein may provide an exploitable discriminatory biomarker of disease severity during *C.*  
310 *trachomatis* infection.

311 **REFERENCES**

- 312 1. <https://www.cdc.gov/std/stats18/default.htm>. Sexually Transmitted Disease  
313 Surveillance 2018: CDC; 2018.
- 314 2. *Chlamydia*. In: Services USDoHaH, ed. 2013 Sexually Transmitted Diseases  
315 Surveillance. Atlanta: Center for Disease Control and Prevention; 2013.
- 316 3. Ting LM, Hsia RC, Haidaris CG, Bavoil PM. Interaction of outer envelope proteins  
317 of *Chlamydia psittaci* GPIC with the HeLa cell surface. Infect Immun.  
318 1995;63(9):3600-8.
- 319 4. Su H, Watkins NG, Zhang Y-X, Caldwell HD. *Chlamydia trachomatis*-host cell  
320 interactions: Role of the chlamydial major outer membrane protein as an adhesin.  
321 Infection & Immunity. 1990;58:1017-25.
- 322 5. Moelleken K, Hegemann JH. The *Chlamydia* outer membrane protein OmcB is  
323 required for adhesion and exhibits biovar-specific differences in  
324 glycosaminoglycan binding. Mol Microbiol. 2008;67(2):403-19.
- 325 6. Crane DD, Carlson JH, Fischer ER, et al. *Chlamydia trachomatis* polymorphic  
326 membrane protein D is a species-common pan-neutralizing antigen. Proc Natl  
327 Acad Sci U S A. 2006;103(6):1894-9.
- 328 7. Baehr W, Zhang Y-X, Joseph T, et al. Mapping antigenic domains expressed by  
329 *Chlamydia trachomatis* major outer membrane protein genes. Proceedings of the  
330 National Academy of Science,U.S.A. 1988;85:4000-4.
- 331 8. Carrasco JA, Tan C, Rank RG, Hsia RC, Bavoil PM. Altered developmental  
332 expression of polymorphic membrane proteins in penicillin-stressed *Chlamydia*  
333 *trachomatis*. Cell Microbiol. 2011;13(7):1014-25.



- 334 9. Fadel S, Eley A. *Chlamydia trachomatis* OmcB protein is a surface-exposed  
335 glycosaminoglycan-dependent adhesin. *J Med Microbiol.* 2007;56(Pt 1):15-22.
- 336 10. Su H, Watkins NG, Zhang YX, Caldwell HD. *Chlamydia trachomatis*-host cell  
337 interactions: role of the chlamydial major outer membrane protein as an adhesin.  
338 *Infect Immun.* 1990;58(4):1017-25.
- 339 11. Stephens RS, Kalman S, Lammel C, et al. Genome sequence of an obligate  
340 intracellular pathogen of humans: *Chlamydia trachomatis*. *Science.*  
341 1998;282(5389):754-9.
- 342 12. Gomes JP, Nunes A, Bruno WJ, Borrego MJ, Florindo C, Dean D. Polymorphisms  
343 in the nine polymorphic membrane proteins of *Chlamydia trachomatis* across all  
344 serovars: evidence for serovar Da recombination and correlation with tissue  
345 tropism. *J Bacteriol.* 2006;188(1):275-86.
- 346 13. Paes W, Dowle A, Coldwell J, Leech A, Ganderton T, Brzozowski A. The  
347 *Chlamydia trachomatis* PmpD adhesin forms higher order structures through  
348 disulphide-mediated covalent interactions. *PLoS One.* 2018;13(6):e0198662.
- 349 14. Tan C, Hsia RC, Shou H, Carrasco JA, Rank RG, Bavoil PM. Variable expression  
350 of surface-exposed polymorphic membrane proteins in *in vitro*-grown *Chlamydia*  
351 *trachomatis*. *Cell Microbiol.* 2010;12(2):174-87.
- 352 15. Tan C, Hsia RC, Shou H, et al. *Chlamydia trachomatis*-infected patients display  
353 variable antibody profiles against the nine-member polymorphic membrane protein  
354 family. *Infect Immun.* 2009;77(8):3218-26.
- 355 16. Taylor BD, Darville T, Tan C, Bavoil PM, Ness RB, Haggerty CL. The role of  
356 *Chlamydia trachomatis* polymorphic membrane proteins in inflammation and

- 357 sequelae among women with pelvic inflammatory disease. *Infect Dis Obstet*  
358 *Gynecol.* 2011;2011:989762.
- 359 17. Peeling RW, Kimani J, Plummer F, et al. Antibody to Hsp60 predicts an increased  
360 risk for chlamydial pelvic inflammatory disease. *J.Infect.Dis.* 1997;175:1153-8.
- 361 18. Wagar EA, Schachter J, Bavoil PM, Stephens RS. Differential human serologic  
362 response to two 60,000 molecular weight *Chlamydia trachomatis* antigens.  
363 *J.Infect.Dis.* 1990;162:922-7.
- 364 19. Rodgers AK, Wang J, Zhang Y, et al. Association of tubal factor infertility with  
365 elevated antibodies to *Chlamydia trachomatis* caseinolytic protease P. *Am J*  
366 *Obstet Gynecol.* 2010;203(5):494 e7- e14.
- 367 20. Mark KS, Brotman RM, Martinez-Greiwe S, Terplan M, Bavoil P, Ravel J.  
368 *Chlamydia* in adolescent/adult reproductive management trial study (CHARM):  
369 Clinical core protocol. *Contemp Clin Trials Commun.* 2019;16:100414.
- 370 21. <https://www.cdc.gov/std/pid/stdfact-pid-detailed.htm>. Pelvic Inflammatory  
371 Disease: CDC; 2020.
- 372 22. Mahony JB, Schachter J, Chernesky MA. Detection of antichlamydial  
373 immunoglobulin G and M antibodies by enzyme linked immunosorbent assay.  
374 *Journal of Clinical Microbiology.* 1983;18:270-5.
- 375 23. Frikha-Gargouri O, Gdoura R, Znazen A, et al. Evaluation of an *in silico* predicted  
376 specific and immunogenic antigen from the OmcB protein for the serodiagnosis of  
377 *Chlamydia trachomatis* infections. *BMC Microbiol.* 2008;8:217.

- 378 24. Amsel R, Totten PA, Spiegel CA, Chen KC, Eschenbach D, Holmes KK.  
379 Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic  
380 associations. *Am J Med.* 1983;74(1):14-22.
- 381 25. Klein SL, Flanagan KL. Sex differences in immune responses. *Nat Rev Immunol.*  
382 2016;16(10):626-38.
- 383 26. Vlcek KR, Li W, Manam S, et al. The contribution of *Chlamydia*-specific CD8(+) T  
384 cells to upper genital tract pathology. *Immunol Cell Biol.* 2016;94(2):208-12.
- 385 27. Ness RB, Soper DE, Richter HE, et al. Chlamydia antibodies, chlamydia heat  
386 shock protein, and adverse sequelae after pelvic inflammatory disease: the PID  
387 Evaluation and Clinical Health (PEACH) Study. *Sex Transm Dis.* 2008;35(2):129-  
388 35.
- 389 28. Stothard DR, Boguslawski G, Jones RB. Phylogenetic analysis of the *Chlamydia*  
390 *trachomatis* major outer membrane protein and examination of potential  
391 pathogenic determinants. *Infect Immun.* 1998;66(8):3618-25.
- 392 29. Baud D, Regan L, Greub G. Comparison of five commercial serological tests for  
393 the detection of anti-*Chlamydia trachomatis* antibodies. *Eur J Clin Microbiol Infect*  
394 *Dis.* 2010;29(6):669-75.
- 395 30. Dumke R, Schnee C, Pletz MW, et al. *Mycoplasma pneumoniae* and *Chlamydia*  
396 spp. infection in community-acquired pneumonia, Germany, 2011-2012. *Emerg*  
397 *Infect Dis.* 2015;21(3):426-34.
- 398 31. Wiesenfeld HC, Sweet RL, Ness RB, Krohn MA, Amortegui AJ, Hillier SL.  
399 Comparison of acute and subclinical pelvic inflammatory disease. *Sex Transm Dis.*  
400 2005;32(7):400-5.

- 401 32. Bas S, Muzzin P, Vischer TL. Chlamydia trachomatis serology: diagnostic value of  
402 outer membrane protein 2 compared with that of other antigens. J Clin Microbiol.  
403 2001;39(11):4082-5.
- 404 33. Gijsen AP, Land JA, Goossens VJ, Leffers P, Bruggeman CA, Evers JL.  
405 *Chlamydia pneumoniae* and screening for tubal factor subfertility. Hum Reprod.  
406 2001;16(3):487-91.
- 407

408 **Figure legends**

409 **FIGURE 1: Schematic representation of the Pmp proteins and recombinant**  
410 **polypeptides used in this study.** Structural features of Pmps are shown; Predicted  
411 signal peptide using Signal 4.0 software (yellow), passenger domain (green), GGA[I/L/V]  
412 (black bars) and FXXN (orange bars) tetrapeptide repeats and autotransporter domain  
413 (red). Recombinant Pmp derivatives based on predicted hydrophilic and antigenic  
414 domains located within the Pmp passenger domain, expressed in GST•tag pGEX-2t  
415 vector (GE Healthcare Biosciences) are shown in light purple (G-rPmpA-F1) and purple  
416 (G-rPmpA-F2, G-rPmpB-F1 and G-rPmp-F2). Passenger domain recombinant proteins  
417 expressed as inclusion bodies in His•tag pET30 (a or b) are in blue (H-rPmp(C to I)-N).

418  
419 **FIGURE 2: High cut-off index antibodies associated with a PID diagnosis.** Sera from  
420 153 female CHARM participants were analyzed by ELISA. Odds ratios (ORs) for PID  
421 positivity when a patient is in the second (black) or third (grey) tertile, compared to the first  
422 tertile are shown. The OR (95% confidence interval) was greater than 1 for G-rOmcB in  
423 both tertiles and H-rOmcB in the second tertile (\*  $p < 0.05$ ) suggesting that high antibody  
424 cut-off indexes for this antigen were significantly associated with PID. Results for H-  
425 rPmpI-N second tertile were borderline significant ( $\ddagger p = 0.075$ ).

426

427

428

429 **Supplemental Digital Content 1.pptx:**

430

431 **Supplemental Digital Content 1. Table S1, which lists the characteristics and**  
432 purification conditions of the recombinant polypeptides.

433

434 **Supplemental Digital Content 1. Figure S1, showing Expression and purification of**  
435 **all the recombinant proteins and peptides used in this study. A)** Coomassie staining  
436 of all recombinant proteins; 1: G-rPmpA-F2, 2: G-rPmpB-F1, 3: G-rPmpB-F2, 4 to 10: H-  
437 rPmp(C to I)-N, 11: G-rClpP, 12: G-rHsp60, 13: G-rMOMP, 14: G-rOmcB, 15: H-rOmcB  
438 and 16: GST only. **B)** Immunoblots. Primary antibodies: guinea pig anti-Pmp A to I (lanes  
439 1-10), mouse anti-ClpP (provided by Dr. Guangming Zhong) (lane 11), rabbit anti-GroEL  
440 (lane 12) and anti-OmcB (lanes 14-15) and goat anti-MOMP (LifeSpan BioSciences) (lane  
441 13) and anti-GST (GE Healthcare Bio-Sciences) (lane 16); secondary antibodies: Alkaline  
442 phosphatase (AP)-conjugated anti-guinea pig, -mouse (KPL, Inc.), -rabbit and -goat  
443 (Sigma-Aldrich). Membranes were revealed with fluorescent alkaline phosphatase  
444 substrate ECF (GE Healthcare Biosciences). \*Apparent molecular weights of protein  
445 bands are listed in Table S1.

446

447 **Supplemental Digital Content 1. Table S2, listing ELISA optimized conditions**

448

449 **Supplemental Digital Content 1. Figure S2, Correlation between G-OmcB and H-**  
450 **OmcB.** OmcB recombinant protein was obtained from 2 different clones using GST•tag  
451 pGEX-2t vector (G-OmcB) and His•tag pET30a vector (H-OmcB). Positive correlation

452 between the ELISA results obtained with these 2 proteins was statistical significant  
453 (0.7462,  $p < 0.001$ ).

454

455 **Supplemental Digital Content 1. Table S3**, showing the ELISA results, sensitivity and  
456 coefficient variation

457

458 **Supplemental Digital Content 1. Table S4** listing tertiles for females only (n=153)

459

460

Figure 1: Marques *et al.*







Figure 2. Marques *et al.*



**TABLES:**

**TABLE 1:** Demographics and sexual behavior compared between genders

	<b>Overall</b>	<b>Male N=120 (%)</b>	<b>Female N=145 (%)</b>	<b>P-value<sup>a</sup></b>
<b>Age, median (IQR)</b>	19.5 (17-21)	20.2 (18-22)	18.9 (17-21)	<b>0.0047<sup>b</sup></b>
<b>Age groups</b>				<b>0.001</b>
<b>≤20 years old</b>	150 (56.60)	55 (45.83)	95 (65.52)	
<b>&gt;20 years old</b>	115 (43.40)	65 (54.17)	50 (34.48)	
<b>Sexual history</b>				
<b>Age of sexual debut</b>				<b>0.007</b>
<b>&lt;13 years old</b>	223 (84.15)	93 (77.50)	130 (89.66)	
<b>13+ years old</b>	42 (15.85)	27 (22.50)	15 (10.34)	
<b>Sexual partners lifetime</b>				<b>&lt;0.001</b>
<b>&lt;6 partners</b>	94 (35.47)	26 (21.67)	68 (46.90)	
<b>6+ partners</b>	171 (64.53)	94 (78.33)	77 (53.10)	
<b>Oral sex</b>	233 (87.92)	109 (90.83)	124 (85.52)	0.186
<b>Anal sex</b>	79 (29.81)	41 (34.17)	38 (26.21)	0.159
<b>Condom use in past 3 months</b>	32 (11.99)	21 (17.50)	11 (7.59)	<b>0.014</b>
<b>Self-reported STI and reproductive health history</b>				
<b>Bacterial STI<sup>c</sup></b>	206 (77.74)	88 (73.33)	118 (81.38)	0.117
<b>Viral STI<sup>d</sup></b>	27 (10.19)	9 (7.50)	18 (12.41)	0.188
<b><i>Trichomonas vaginalis</i></b>	N/A <sup>e</sup>	N/A	28 (19.31)	N/A
<b>BV</b>	N/A	N/A	15 (10.34)	N/A
<b>PID</b>	N/A	N/A	6 (4.14)	N/A
<b>Physician assessment<sup>f</sup></b>				
<b>PID</b>	N/A	N/A	33 (22.76)	N/A
<b>STI Diagnostic Laboratory tests (current)</b>				
<b>HIV</b>	18 (6.79)	8 (6.67)	10 (6.90)	0.941

<b>RPR/ syphilis</b>	2 (0.75)	1 (0.83)	1 (0.69)	0.893
<b>GC/ gonorrhoea</b>	20 (7.55)	10 (8.33)	10 (6.90)	0.659

<sup>a</sup>P-values from chi-square, unless otherwise indicated

<sup>b</sup>P-values from Rank-sum Wilcoxon

<sup>c</sup>gonorrhoea, chlamydia and syphilis

<sup>d</sup>HPV, Herpes and HIV

N/A, not applicable, diagnosed in women only

PID assessment was performed by a physician following CDC criteria

**TABLE 2:** Association of demographic, biological and sexual behaviors in 33 women with a PID diagnosis among the 145 women in the study

	Unadjusted analysis			Adjusted analysis	
	Overall	Odd ratio (95% CI)	p-value	Odd ratio (95% CI)	p-value <sup>a</sup>
<b>Age groups</b>			0.796		0.523
≤20 years old	95 (65.52)	1		1	
>20 years old	50 (34.48)	1.11 (0.50, 2.50)		0.75 (0.35, 1.83)	
<b>Sexual history</b>					
<b>Age of sexual debut</b>			0.135		0.326
<13 years old	107 (73.79)	1.89 (0.82, 4.35)		1.60 (0.63, 4.05)	
13+ years old	38 (26.21)	1		1	
<b>Sexual partners lifetime</b>			0.079		0.274
<6 partners	68 (46.90)	1		1	
6+ partners	77 (53.10)	2.07 (0.92, 4.67)		1.64 (0.67, 4.00)	
<b>Receptive oral sex ever (vs. never)</b>	119 (82.07)	2.58 (0.72, 9.22)	0.144	2.00 (1.00, 1.00)	0.596
<b>Anal sex ever (vs. never)</b>	38 (26.21)	1.07 (0.45, 2.57)	0.874	0.89 (0.36, 2.24)	0.808
<b>No condom use in past 3 months</b>	134 (92.41)	N/A <sup>b</sup>	N/A	N/A <sup>b</sup>	N/A
<b>Self-reported prior STI</b>					
<b>Bacterial STI<sup>c</sup></b>	118 (81.38)	2.73 (0.77, 9.71)	0.121	2.19 (0.59, 8.22)	0.244
<b>Viral STI<sup>d</sup></b>	18 (12.41)	0.97 (0.29, 3.16)	0.954	0.54 (0.14, 2.09)	0.373
<b><i>Trichomonas vaginalis</i></b>	28 (19.31)	2.79 (1.15, 6.80)	<b>0.023</b>	2.36 (0.89, 6.25)	<b>0.083</b>
<b>BV</b>	15 (10.34)	2.54 (0.83, 7.77)	0.101	2.19 (0.68, 7.04)	0.191
<b>PID</b>	6 (4.14)	19.82 (2.23, 176.52)	<b>0.007</b>	-	

<b>STI Diagnostic Laboratory tests (current)<sup>c</sup></b>					
<b>HIV</b>	10 (6.90)	0.36 (0.04, 2.93)	0.338	0.25 (0.03, 2.32)	0.223
<b>GC/ gonorrhea</b>	10 (6.90)	0.84 (0.17, 4.16)	0.829	1.00 (0.19, 5.20)	0.998

<sup>a</sup>P-values from logistic regression

<sup>b</sup>None of the female participants positive for PID used condoms

<sup>c</sup>gonorrhoea and chlamydia (syphilis was not analyzed because it was only detected in 1 female)

<sup>d</sup>HPV, Herpes and HIV

**TABLE 3:** *Chlamydia* antigenic biomarkers compared between genders (categorized by tertiles)

	Overall	Male N=122 (%)	Female N=145 (%)	P-value <sup>a</sup>
<b>G-rPmpA-F2</b>				<b>0.068</b>
<0.41	89 (33.58)	45 (37.50)	44 (30.34)	
0.41 – 1.04	88 (33.21)	44 (36.67)	44 (30.34)	
>1.04	88 (33.21)	31 (25.83)	57 (39.31)	
<b>G-rPmpB-F1</b>				0.586
<0.28	89 (33.58)	43 (35.83)	46 (31.72)	
0.28 – 0.69	88 (33.21)	41 (34.17)	47 (32.41)	
>0.69	88 (33.21)	36 (30.00)	52 (35.86)	
<b>G-rPmpB-F2</b>				0.417
<0.55	90 (33.96)	42 (35.00)	48 (33.10)	
0.55 – 2.40	87 (32.83)	43 (35.83)	44 (30.34)	
>2.40	88 (33.21)	35 (29.17)	53 (36.55)	
<b>H-rPmpC-N</b>				<b>0.001</b>
<8.75	89 (33.58)	54 (45.00)	35 (24.14)	
8.75 – 20.47	88 (33.21)	35 (29.17)	53 (36.55)	
>20.47	88 (33.21)	31 (25.83)	57 (39.31)	
<b>H-rPmpD-N</b>				0.195
<1.88	89 (33.58)	47 (39.17)	42 (28.97)	
1.88 – 4.10	88 (33.21)	38 (31.67)	50 (34.48)	
>4.10	88 (33.21)	35 (29.17)	53 (36.55)	
<b>H-rPmpE-N</b>				<b>0.063</b>
<6.13	89 (33.58)	46 (38.33)	43 (29.66)	
6.13 – 14.94	88 (33.21)	43 (35.83)	45 (31.03)	
>14.94	88 (33.21)	31 (25.83)	57 (39.31)	
<b>H-rPmpF-N</b>				<b>0.020</b>

<b>&lt;5.52</b>	89 (33.58)	51 (42.50)	38 (26.21)	
<b>5.52 – 19.85</b>	88 (33.21)	34 (28.33)	54 (37.24)	
<b>&gt;19.85</b>	88 (33.21)	35 (29.17)	53 (36.55)	
<b>H-rPmpG-N</b>				<b>0.199</b>
<b>&lt;0.79</b>	89 (33.58)	44 (36.67)	45 (31.03)	
<b>0.79 – 3.69</b>	88 (33.21)	43 (35.83)	45 (31.03)	
<b>&gt;3.69</b>	88 (33.21)	33 (27.50)	55 (37.93)	
<b>H-rPmpH-N</b>				<b>0.018</b>
<b>&lt;1.93</b>	89 (33.58)	46 (38.33)	43 (29.66)	
<b>1.93 – 5.17</b>	88 (33.21)	45 (37.50)	43 (29.66)	
<b>&gt;5.17</b>	88 (33.21)	29 (24.17)	59 (40.69)	
<b>H-rPmpI-N</b>				<b>0.105</b>
<b>&lt;4.19</b>	89 (33.58)	46 (38.33)	43 (29.66)	
<b>4.19 – 10.68</b>	88 (33.21)	42 (35.00)	46 (31.72)	
<b>&gt;10.68</b>	88 (33.21)	32 (26.67)	56 (38.62)	
<b>G-rClpP</b>				<b>0.709</b>
<b>&lt;0.68</b>	89 (33.58)	39 (32.50)	50 (34.48)	
<b>0.68 – 2.08</b>	88 (33.21)	38 (31.67)	50 (34.48)	
<b>&gt;2.08</b>	88 (33.21)	43 (35.83)	45 (31.03)	
<b>G-rGroEL</b>				<b>0.952</b>
<b>&lt;4.11</b>	89 (33.58)	40 (33.33)	49 (33.79)	
<b>4.11 – 13.58</b>	88 (33.21)	39 (32.50)	49 (33.79)	
<b>&gt;13.58</b>	88 (33.21)	41 (34.17)	47 (32.41)	
<b>G-rMOMP</b>				<b>0.011</b>
<b>&lt;1.64</b>	89 (33.58)	51 (42.50)	38 (26.21)	
<b>1.64 – 4.61</b>	88 (33.21)	32 (25.83)	57 (39.31)	
<b>&gt;4.61</b>	88 (33.21)	38 (31.67)	50 (34.48)	

<b>G-rOmcB</b>				0.830
<b>&lt;1.94</b>	89 (33.58)	40 (33.33)	49 (33.79)	
<b>1.94 – 4.44</b>	88 (33.21)	42 (35.00)	46 (31.72)	
<b>&gt;4.44</b>	88 (33.21)	38 (31.67)	50 (34.48)	
<b>H-rOmcB</b>				0.835
<b>&lt;7.00</b>	89 (33.58)	38 (31.67)	51 (35.17)	
<b>7.00 – 24.83</b>	88 (33.21)	41 (34.17)	47 (32.41)	
<b>&gt;24.83</b>	88 (33.21)	41 (34.17)	47 (32.41)	
<b>Ct purified EBs<sup>b</sup></b>				0.308
<b>&lt;1.96</b>	89 (33.58)	43 (35.83)	46 (31.72)	
<b>1.96 – 5.22</b>	88 (33.21)	43 (35.83)	45 (31.03)	
<b>&gt;5.22</b>	88 (33.21)	34 (28.33)	54 (37.24)	

<sup>a</sup>P-values from chi-square

<sup>b</sup>*Chlamydia trachomatis* serovar E purified EBs



**TABLE 4:** Assessing associations between the levels of the factors (in tertiles) associated with PID diagnosis (tertiles calculated only for females, described on Table S4)

Biomarkers	second vs first		third vs first	
	Unadjusted Odds Ratio (95% CI)	p-value	Unadjusted Odds Ratio (95% CI)	p-value <sup>a</sup>
G-rPmpA-F2	0.66 (0.26 – 1.67)	0.379	0.58 (0.22 – 1.50)	0.258
G-rPmpB-F1	0.64 (0.24 – 1.67)	0.362	0.82 (0.33 – 2.08)	0.680
G-rPmpB-F2	1.83 (0.70 – 4.75)	0.214	1.17 (0.43 – 3.19)	0.760
H-rPmpC-N	0.92 (0.36 – 2.34)	0.855	0.81 (0.31 – 2.11)	0.667
H-rPmpD-N	1.03 (0.41- 2.59)	0.954	0.71 (0.27 – 1.89)	0.494
H-rPmpE-N	1.77 (0.70 – 4.47)	0.225	0.78 (0.28 – 2.18)	0.636
H-rPmpF-N	0.71 (0.27 – 1.89)	0.494	1.03 (0.41 – 2.59)	0.954
H-rPmpG-N	1.57 (0.63 – 3.89)	0.330	0.59 (0.21 – 1.68)	0.322
H-rPmpH-N	0.66 (0.26 – 1.67)	0.379	0.58 (0.22 – 1.50)	0.258
H-rPmpI-N	2.33 (0.88 – 6.16)	<b>0.088</b>	1.35 (0.48 – 3.77)	0.569
G-ClpP	0.92 (0.37 – 2.29)	0.863	0.55 (0.21 – 1.49)	0.242
G-rGroEL	1.48 (0.56 – 3.93)	0.429	1.48 (0.56 – 3.93)	0.429
G-rMOMP	1.48 (0.56 – 3.93)	0.429	1.48 (0.56 – 3.93)	0.429
G-rOmcB	2.95 (1.03 – 8.49)	<b>0.045</b>	2.66 (0.92 – 7.72)	<b>0.072</b>
H-rOmcB	2.62 (0.83 – 8.21)	<b>0.099</b>	4.83 (1.61 – 14.47)	<b>0.005</b>
Ct purified EBs <sup>b</sup>	1.52 (0.55 – 4.20)	0.415	2.11 (0.79 – 5.63)	0.135
	second vs first		third vs first	
	Adjusted <sup>c</sup> Odds Ratio (95% CI)	p-value	Adjusted <sup>c</sup> Odds Ratio (95% CI)	p-value
G-rPmpA-F2	0.68 (0.26 – 1.79)	0.432	0.76 (0.27 – 2.14)	0.606
G-rPmpB-F1	0.80 (0.28 – 2.25)	0.668	0.98 (0.35 – 2.69)	0.962
G-rPmpB-F2	2.00 (0.72 – 5.52)	0.181	1.01 (0.35 – 2.92)	0.983
H-rPmpC-N	0.98 (0.36 – 2.66)	0.974	0.85 (0.31 – 2.33)	0.752

<b>H-rPmpD-N</b>	1.07 (0.41 – 2.81)	0.892	0.86 (0.31 – 2.40)	0.774
<b>H-rPmpE-N</b>	2.21 (0.80 – 6.10)	0.128	1.06 (0.35 – 3.19)	0.922
<b>H-rPmpF-N</b>	0.77 (0.28 – 2.16)	0.622	1.38 (0.51 – 3.75)	0.529
<b>H-rPmpG-N</b>	1.96 (0.74 – 5.17)	0.175	0.68 (0.22 – 2.03)	0.486
<b>H-rPmpH-N</b>	0.74 (0.28 – 1.98)	0.551	0.71 (0.25 – 1.99)	0.510
<b>H-rPmpI-N</b>	2.52 (0.89 – 7.11)	<b>0.081</b>	1.77 (0.59 – 5.36)	0.310
<b>G-ClpP</b>	0.80 (0.31 – 2.11)	0.657	0.51 (0.18 – 1.45)	0.208
<b>G-rGroEL</b>	1.28 (0.47 – 3.49)	0.634	1.40 (0.51 – 3.87)	0.517
<b>G-rMOMP</b>	1.32 (0.48 – 3.63)	0.592	1.39 (0.50 – 3.85)	0.529
<b>G-rOmcB</b>	2.58 (0.87 – 7.63)	<b>0.087</b>	2.56 (0.86 – 7.65)	<b>0.091</b>
<b>H-rOmcB</b>	2.31 (0.72 – 7.46)	0.160	4.22 (1.37 – 13.01)	<b>0.012</b>
<b>Ct purified EBs<sup>c</sup></b>	1.59 (0.56 – 4.57)	0.385	2.23 (0.80 – 6.24)	0.127

<sup>a</sup> P-values from logistic regression

<sup>b</sup> *Chlamydia trachomatis* serovar E purified EBs

<sup>c</sup> Adjusted for age, sexual partners ever, *Trichomonas vaginalis* and Bacterial Vaginosis (BV)